CD47 and chronic myelogenous leukemia, BCR-ABL1 positive: Conversely, the selective HDAC6 inhibitor Rocilinostat, which did not induce SLFN11 in K562 chronic myelogenous leukemia or HT1080 fibrosarcoma cells (29), was 1.51-fold less potent for CD47− vs. WT cells in the CellTiter Glo assay (Figure 3B) and was less potent for inhibiting proliferation of CD47− cells (Figure 3D).